Introduction
Ankylosing spondylitis (AS) — now more broadly classified under the term axial spondyloarthritis (axSpA) — is a chronic inflammatory arthritis that primarily affects the spine and sacroiliac joints. It is characterized by inflammatory back pain, progressive spinal stiffness, and in advanced cases, fusion of the vertebrae — a process called ankylosis that can lead to a rigid, bamboo-like spine.
AS is not a rare condition. It affects approximately 0.1–0.5% of the global population, with a strong genetic association with the HLA-B27 antigen. It predominantly affects young adults, with symptoms typically beginning before the age of 45 — often in the late teens or twenties. Delayed diagnosis is common, with an average diagnostic delay of 8–10 years from symptom onset.
For international patients and expatriates in Shanghai, early diagnosis and access to specialist rheumatology care are critical. Modern treatments — particularly biologic therapies — have transformed outcomes for AS patients, making early intervention more important than ever. This guide provides a comprehensive overview of ankylosing spondylitis for the international community in Shanghai.
Understanding Axial Spondyloarthritis
Ankylosing spondylitis sits within the broader family of spondyloarthritis (SpA) — a group of related inflammatory conditions sharing common features including axial (spinal) involvement, peripheral arthritis, enthesitis (inflammation at tendon and ligament insertion sites), and extra-articular manifestations.
The current classification distinguishes two forms of axial SpA:
- Radiographic axial SpA (r-axSpA) = Ankylosing Spondylitis: Structural damage (sacroiliitis) is visible on plain X-ray. This is the classical, more advanced form.
- Non-radiographic axial SpA (nr-axSpA): Inflammatory changes are present on MRI but not yet visible on X-ray. Symptoms and disease burden can be equally significant. Increasingly recognized and treated.
Symptoms
Axial (Spinal) Symptoms
The hallmark of AS is inflammatory back pain — which has distinct features that differentiate it from the far more common mechanical back pain:
- Onset before age 45
- Insidious (gradual) onset over weeks to months
- Duration of more than 3 months
- Worse with rest and inactivity — particularly in the second half of the night and early morning
- Improves with exercise and movement
- Morning stiffness lasting more than 30–60 minutes
- Alternating buttock pain (reflecting sacroiliac joint inflammation)
As the disease progresses, inflammation can spread up the spine, causing stiffness and reduced spinal mobility. In severe, longstanding disease, vertebral fusion leads to a fixed, rigid spine with characteristic forward stooping posture (kyphosis).
Peripheral Manifestations
- Peripheral arthritis: Asymmetric arthritis of large joints (hips, knees, shoulders, ankles). Hip involvement is particularly common in AS and can be severely disabling.
- Enthesitis: Inflammation at tendon and ligament insertion sites. Classic sites include the Achilles tendon insertion, plantar fascia (heel pain), and costochondral junctions (chest pain with breathing).
- Dactylitis: “Sausage digit” — diffuse swelling of an entire finger or toe.
Extra-Articular Manifestations
- Acute anterior uveitis (AAU): Inflammation of the iris — the most common extra-articular manifestation, occurring in up to 40% of AS patients. Presents as sudden-onset unilateral eye redness, pain, and photophobia. Requires urgent ophthalmological evaluation to prevent vision loss.
- Inflammatory bowel disease (IBD): Crohn’s disease or ulcerative colitis occurs in approximately 5–10% of AS patients. Subclinical gut inflammation is present in up to 60%.
- Psoriasis: Skin psoriasis occurs in approximately 10% of AS patients.
- Cardiac involvement: Aortic regurgitation and conduction abnormalities in longstanding disease.
- Pulmonary involvement: Apical lung fibrosis in advanced disease; restrictive lung function from chest wall rigidity.
- Osteoporosis: Increased fracture risk, particularly vertebral fractures, even in early disease.
Causes & Risk Factors
- HLA-B27: The strongest known genetic risk factor. Approximately 90–95% of AS patients in Western populations are HLA-B27 positive. In Asian populations (including Chinese), the HLA-B27 positivity rate in AS is similarly high. However, only 1–5% of HLA-B27 positive individuals develop AS — additional genetic and environmental factors are required.
- Family history: First-degree relatives of AS patients have a significantly elevated risk.
- Sex: AS is 2–3 times more common in men, though women are increasingly recognized as affected — often with milder radiographic changes but similar symptom burden.
- Age of onset: Typically before 45, with peak onset in the late teens to thirties.
- Gut microbiome: Emerging evidence links gut dysbiosis and intestinal inflammation to AS pathogenesis.
Diagnosis
Diagnosis of AS requires a combination of clinical assessment, laboratory testing, and imaging. The average diagnostic delay of 8–10 years reflects the insidious onset and frequent misattribution of symptoms to mechanical back pain.
- Clinical assessment: Detailed history of back pain characteristics, morning stiffness, response to NSAIDs, family history, and extra-articular features. Physical examination assesses spinal mobility (Schober test, chest expansion, occiput-to-wall distance) and sacroiliac joint tenderness.
- HLA-B27 testing: A blood test for the HLA-B27 antigen. Positive in the majority of AS patients. A useful diagnostic aid but not diagnostic alone — many HLA-B27 positive individuals do not have AS.
- Inflammatory markers: CRP (C-reactive protein) and ESR (erythrocyte sedimentation rate) are elevated in approximately 50–70% of AS patients. Normal inflammatory markers do not exclude AS.
- Sacroiliac joint X-ray: Detects structural sacroiliitis (erosions, sclerosis, fusion) in radiographic axSpA. Changes may take years to develop.
- MRI of sacroiliac joints and spine: The most sensitive imaging modality for early AS. Detects bone marrow edema (active inflammation) before structural changes are visible on X-ray. Essential for diagnosing non-radiographic axSpA. Available at major Shanghai hospitals.
- Whole spine X-ray: Assesses for syndesmophytes (bony bridges between vertebrae) and the classic “bamboo spine” appearance in advanced disease.
Treatment
The goals of AS treatment are to reduce pain and stiffness, maintain spinal mobility and function, prevent structural damage and deformity, and manage extra-articular manifestations. Treatment is multidisciplinary, combining medication, physiotherapy, and patient education.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
NSAIDs are the first-line pharmacological treatment for AS. They provide rapid and often dramatic relief of inflammatory back pain and stiffness. Continuous NSAID use (rather than on-demand) may also slow radiographic progression. Commonly used NSAIDs include indomethacin, diclofenac, naproxen, and celecoxib — all available in China. Long-term NSAID use requires monitoring of kidney function and gastrointestinal health.
Physiotherapy & Exercise
Regular physiotherapy and exercise are essential components of AS management and cannot be replaced by medication alone. Key benefits include maintaining spinal mobility, improving posture, strengthening paraspinal muscles, and reducing pain. Recommended activities include:
- Daily stretching and range-of-motion exercises for the spine
- Swimming and hydrotherapy — particularly beneficial as water supports the body and allows full range of motion
- Yoga and Pilates (modified for AS)
- Walking and cycling
- Avoid high-impact contact sports that risk spinal injury, particularly in patients with advanced spinal fusion
AS-specific physiotherapy programs are available at rehabilitation departments in Shanghai’s leading hospitals. CMCS can coordinate referrals.
Biologic Disease-Modifying Antirheumatic Drugs (bDMARDs)
Biologic therapies have revolutionized AS treatment. They are indicated when patients have persistently active disease despite adequate NSAID therapy.
- TNF inhibitors (TNFi): The first class of biologics approved for AS. Highly effective at reducing inflammation, improving symptoms, and potentially slowing radiographic progression. Options include etanercept, adalimumab, infliximab, golimumab, and certolizumab pegol. All are available in China, with several available as biosimilars at reduced cost.
- IL-17A inhibitors: Secukinumab and ixekizumab are highly effective alternatives to TNF inhibitors, particularly in patients who have failed or cannot tolerate TNFi. Secukinumab is approved and available in China. IL-17 inhibitors are preferred over TNFi in patients with concurrent IBD — as IL-17 inhibitors may worsen IBD.
- IL-23 inhibitors (e.g., risankizumab): Emerging evidence supports efficacy in axSpA; availability in China for this indication is evolving.
- JAK inhibitors (e.g., upadacitinib, tofacitinib): Oral targeted synthetic DMARDs that are effective for AS. Upadacitinib is approved for AS in China. Require monitoring for cardiovascular risk, infections, and malignancy.
Conventional DMARDs
Sulfasalazine and methotrexate have limited efficacy for axial disease but may be used for peripheral arthritis. They are not recommended as primary treatment for spinal AS.
Corticosteroids
Systemic corticosteroids have limited efficacy in AS and are generally avoided for long-term use. Local corticosteroid injections into sacroiliac joints or peripheral joints can provide temporary relief.
Surgery
Surgery is reserved for specific complications of advanced AS:
- Total hip replacement: For severe hip joint destruction causing significant disability. Highly effective and commonly performed in AS patients at Shanghai’s leading orthopedic centers.
- Spinal osteotomy: For severe fixed kyphotic deformity causing functional impairment or inability to look forward. A complex procedure performed at specialized spinal surgery centers.
- Spinal fracture fixation: AS patients with fused spines are at high risk of spinal fractures from even minor trauma. Any neck or back pain after trauma in an AS patient requires urgent imaging.
Monitoring & Long-Term Management
Regular monitoring is essential to assess disease activity, treatment response, and complications:
- Disease activity scores: BASDAI (Bath AS Disease Activity Index) and ASDAS (AS Disease Activity Score) — standardized questionnaires used to guide treatment decisions
- Inflammatory markers (CRP, ESR) at regular intervals
- Spinal X-rays every 2 years to assess radiographic progression
- MRI when clinical assessment suggests active inflammation not captured by X-ray
- Bone density (DEXA scan) — osteoporosis screening and monitoring
- Ophthalmology review — annual screening and prompt evaluation of any eye symptoms
- Cardiovascular risk assessment — AS is associated with increased cardiovascular risk
Living with AS in Shanghai
- Medications: NSAIDs, sulfasalazine, and most biologic therapies (including TNF inhibitors and secukinumab) are available in China. Biosimilar versions of several TNF inhibitors are available at significantly reduced cost. CMCS can assist with medication access and insurance navigation.
- Physiotherapy: Rehabilitation departments at major Shanghai hospitals offer physiotherapy. English-language physiotherapy services are available at some international clinics.
- Workplace ergonomics: Prolonged sitting worsens AS symptoms. Use a standing desk where possible, take regular movement breaks, and ensure your workstation supports good posture.
- Specialist care: Rheumatology departments at Ruijin Hospital, Zhongshan Hospital, and Renji Hospital have experienced rheumatologists with expertise in spondyloarthritis. CMCS can facilitate access with full interpretation support.
- Spinal precautions: Patients with advanced spinal fusion should avoid activities with high risk of spinal trauma. Wear a seatbelt at all times. Inform any treating doctor or dentist of your AS diagnosis, as spinal positioning during procedures requires care.
How China Medical Concierge Shanghai (CMCS) Can Help
AS is a lifelong condition requiring consistent specialist care, medication management, and physiotherapy — all of which can be challenging to coordinate in a foreign healthcare system. CMCS provides:
- Specialist matching: Connecting you with experienced rheumatologists at Shanghai’s leading hospitals with expertise in spondyloarthritis
- Appointment booking: Priority scheduling and full administrative coordination
- Medical interpretation: Professional interpreters for all consultations, imaging reviews, and treatment discussions
- Medication access: Guidance on obtaining biologic therapies in China, including biosimilars and newer agents such as JAK inhibitors
- Insurance coordination: Liaising with your international health insurer for biologic therapy approvals and ongoing treatment claims
- Physiotherapy coordination: Referrals to AS-experienced physiotherapists in Shanghai
- Ophthalmology coordination: Urgent referral for acute uveitis and routine eye screening
- Orthopedic coordination: Facilitating access to hip replacement and spinal surgery specialists when required
📩 Contact CMCS today for a free initial consultation.
Frequently Asked Questions
What is the difference between ankylosing spondylitis and regular back pain?
Inflammatory back pain from AS has characteristic features: onset before 45, gradual onset, duration over 3 months, worse with rest and at night, better with exercise, and associated with morning stiffness lasting more than 30 minutes. Mechanical back pain is typically worsened by activity and relieved by rest. If your back pain has inflammatory features, see a rheumatologist for evaluation.
Is HLA-B27 testing available in Shanghai?
Yes. HLA-B27 blood testing is widely available at major Shanghai hospitals. A positive result significantly increases the probability of AS in a patient with inflammatory back pain, but is not diagnostic alone. CMCS can coordinate testing and specialist interpretation.
Can AS be cured?
There is currently no cure for AS. However, modern biologic therapies can achieve remission or very low disease activity in many patients, preventing structural damage and preserving quality of life. Early diagnosis and treatment are key to the best outcomes.
Are biologic therapies available in China?
Yes. TNF inhibitors (including biosimilars) and IL-17 inhibitors (secukinumab) are approved and available in China for AS. JAK inhibitors (upadacitinib) are also approved. CMCS can assist with accessing these therapies and navigating insurance pre-authorization.
Can I exercise with ankylosing spondylitis?
Yes — and you should. Regular exercise is one of the most important components of AS management. Swimming, walking, cycling, yoga, and AS-specific physiotherapy are all beneficial. Exercise maintains spinal mobility and reduces pain. Avoid high-impact contact sports if you have advanced spinal fusion.
Is AS covered by international health insurance?
Yes. AS diagnosis, specialist consultations, imaging (MRI, X-ray), laboratory tests, and prescription medications — including biologic therapies — are typically covered by international health insurance. Coverage for specific biologics may require pre-authorization. CMCS can verify your coverage and manage the authorization process.
0 則留言